Brief: IBA: Japanese Approval For Reimbursement Of Amyloid-PET Diagnostic Neuraceq In Alzheimer's Disease
Dec 13 (Reuters) - Ion Beam Applications SA IBAB.BR :
* IBA, CMI AND LIFE MOLECULAR IMAGING ANNOUNCE JAPANESE
APPROVAL
FOR THE REIMBURSEMENT OF AMYLOID-PET DIAGNOSTIC NEURACEQ® IN
ALZHEIMER'S DISEASE
* JAPANESE MINISTRY OF HEALTH HAS APPROVED REIMBURSEMENT BY
GOVERNMENTAL HEALTH INSURANCE OF AMYLOID POSITRON EMISSION
TOMOGRAPHY (PET) DIAGNOSTIC NEURACEQ® (FLORBETABEN 18F)
* NEURACEQ IS FIRST AMYLOID PET DIAGNOSTIC TOOL REIMBURSED
IN
JAPAN
Source text for Eikon: ID:nGNEbNtGH3
Further company coverage: IBAB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ion Beam Applications SA
See all newsBrief: IBA Signs Contract With Government Of Assam For India's State-Run Proton Therapy Center
Brief: Iba Signs Contract For Be Efficient Sterilization Solution In Germany
Brief: IBA Says First Patient Treated In C-Flash-01 Conformalflash Clinical Trial
Brief: IBA Selected To Support The US Expansion Of Radiopharmaceutical Producer
Brief: IBA And Telix Strengthen Ties Through Agreement To Distribute ARTMS QIS